Oric Pharmaceuticals, Inc. (ORIC)

In the past six months, ORIC's stock has been impacted by earnings reports, clinical trial progress, analyst ratings, a capital raise, a workforce reduction, and stock performance. ORIC last reported earnings on November 13, 2025, with shares gaining 0.5% the next day. In January 2026, ORIC announced promising results from clinical trials for ORIC-944 and enozertinib, outlining operational highlights for 2025 and upcoming milestones. Several equities analysts issued "Outperform" or "Buy" ratings, while Wall Street Zen lowered ORIC from a "hold" to a "sell" rating. ORIC raised $244 million in 2025 and laid off 20% of its employees to focus resources on its lead oncology drugs. The share price as of January 9, 2026, was $9.15, representing an increase of 6.40% from January 13, 2025.

Information regarding the demand seasonality for Oric Pharmaceuticals' products and services is not explicitly available. Analysis of the stock's seasonal performance suggests a seasonal trend where a "Buy Date" of October 7 and a "Sell Date" of January 4 has historically resulted in a geometric average return of 37.64% above the S&P 500 Total Return Index. This is related to stock trading patterns and not directly to the demand for the company's pharmaceutical products.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome cancer resistance, operating within the Health Care sector. The company's pipeline includes ORIC-944 (rinzimetostat) for prostate cancer, ORIC-114 (enozertinib) for non-small cell lung cancer and breast cancer, and ORIC-533 for multiple myeloma and hormone receptor-positive breast cancer. The company's strategy centers on addressing the biological mechanisms that allow cancer to evade therapy.

Oric Pharmaceuticals' discovery and development activities are primarily within the United States, with its operational base in South San Francisco and San Diego, California. The company concentrates its clinical development efforts within the U.S., leveraging its California-based headquarters and offices. Its ultimate commercialization strategy aims to reach major global oncology markets.

Oric Pharmaceuticals' brand reputation has been influenced by its clinical trial progress and analyst sentiment. The company has received a "Moderate Buy" consensus rating from analysts. Positive clinical trial results for ORIC-944 and enozertinib have contributed positively to its scientific and market perception. The successful capital raise in 2025 also indicates investor confidence. The layoff of 20% of its workforce in August 2025 was framed as a strategic move to focus resources on its lead clinical programs.

Oric Pharmaceuticals, Inc. has a significant institutional ownership base, with 319 institutional owners and shareholders holding a total of 116,225,270 shares. Institutional ownership accounts for 95.05% of the stock, while insider ownership is 5.55% as of July 30, 2025. Major institutional owners include Nextech Invest, Ltd., EcoR1 Capital, LLC, VR Adviser, LLC, Viking Global Investors Lp and Pfizer Inc.